Table 1.
Colorectal cancer (CRC) |
Colorectal adenomas |
|||||||||
---|---|---|---|---|---|---|---|---|---|---|
cases |
controls |
cases |
controls |
|||||||
Characteristic | n | % | n | % | p-value | n | % | n | % | p-value |
Cohort participation1 | ||||||||||
CLUE I only (1974) | 354 | 57.9 | 354 | 57.9 | 0 | 0.0 | 0 | 0.0 | ||
CLUE II only (1989) | 139 | 22.7 | 139 | 22.7 | 123 | 100.0 | 123 | 100.0 | ||
CLUE I and II | 118 | 19.3 | 118 | 19.3 | matched | 0 | 0.0 | 0 | 0.0 | matched |
Age in years (mean +/-SD)1 | 56.2 +/− 12.4 | 56.2 +/− 12.3 | matched | 55.1 +/− 9.7 | 54.9 +/− 9.6 | matched | ||||
Sex1 | ||||||||||
male | 269 | 44.0 | 269 | 44.0 | 61 | 49.6 | 61 | 49.6 | ||
female | 342 | 56.0 | 342 | 56.0 | matched | 62 | 50.4 | 62 | 50.4 | matched |
Race1 | ||||||||||
White | 600 | 98.2 | 600 | 98.2 | 123 | 100.0 | 123 | 100.0 | ||
other | 11 | 1.8 | 00 | 1.8 | matched | 0 | 0.0 | 0 | 0.0 | matched |
Smoking status | ||||||||||
current | 158 | 21.7 | 154 | 21.1 | 21 | 17.1 | 15 | 12.2 | ||
former | 230 | 31.6 | 197 | 27.0 | 52 | 42.3 | 41 | 33.3 | ||
never | 341 | 46.8 | 378 | 51.9 | 0.18 | 50 | 40.7 | 67 | 54.5 | 0.08 |
Body mass index (kg/m2)3 | ||||||||||
< 25 | 102 | 39.7 | 104 | 40.5 | 52 | 42.3 | 51 | 41.5 | ||
25–30 | 103 | 40.1 | 110 | 42.8 | 49 | 39.8 | 54 | 43.9 | ||
30+ | 52 | 20.2 | 43 | 16.7 | 0.51 | 22 | 17.9 | 18 | 14.6 | 0.71 |
NSAID use at baseline2 | ||||||||||
Yes | 176 | 24.1 | 209 | 28.7 | 38 | 30.9 | 29 | 23.6 | ||
No | 553 | 75.9 | 520 | 71.3 | 0.05 | 85 | 69.1 | 94 | 76.4 | 0.18 |
Family history of CRC3 | ||||||||||
no | 124 | 78.0 | 150 | 86.7 | 86 | 71.7 | 98 | 83.8 | ||
yes | 35 | 22.0 | 23 | 13.3 | 0.04 | 34 | 28.33 | 19 | 16.2 | 0.03 |
Recent hormone use3,4 | ||||||||||
none | 178 | 87.7 | 185 | 89.4 | 49 | 81.7 | 42 | 67.7 | ||
any | 25 | 12.3 | 22 | 10.6 | 0.64 | 11 | 18.3 | 20 | 32.3 | 0.10 |
matching factors
non-steroidal anti-inflammatory drugs (NSAID) use within 48 hours prior to blood draw
data obtained from CLUE II participants only
data presented for females only